CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- DEFA14A Proxy Proxy Materials
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Option exercise CEO acquired 109,768 shares (option exercise)
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change · Bylaws or fiscal year change
- 4 Open-market sale General Counsel sold 5,268 shares at $2.09 ($10,986)
- 4 Open-market sale CEO sold 20,223 shares at $2.09 ($42,175)
- 4 Open-market sale SVP, Finance and Accounting sold 2,971 shares at $2.09 ($6,196)
- 4 Open-market sale SVP, Chief Scientific Officer sold 12,795 shares at $2.09 ($26,684)
- 4 Open-market sale Chief Business Officer sold 6,562 shares at $2.09 ($13,685)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Results of operations
- 10-K Report Annual Report
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
Page 9 of 41 · 801 filings